$KYNB

KYNTRA BIO, INC.

Kyntra Bio is a biopharmaceutical company developing therapies in cancer biology and anemia. Its oncology program includes FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and potentially other cancers, and FG-3180, a related PET imaging agent being evaluated as a biomarker. The company is also developing roxadustat for anemia associated with lower-risk myelodysplastic syndromes. Roxadustat is approved in several countries for anemia in chronic kidney disease. Kyntra Bio retains roxadustat rights in the United States, Canada, Mexico and markets not held by AstraZeneca or licensed to Astellas. Astellas commercializes the drug in Europe and Japan. Kyntra Bio earns money primarily through collaboration agreements, including agreements with Astellas for roxadustat development and commercialization. It uses third-party manufacturers for its products and candidates. Kyntra Bio is headquartered in San Francisco, California.

0
5
0

No SEC Form 4 filings for $KYNB in the last 30 days.

See all $KYNB insider activity →

Kyntra Bio earnings beat by $3.77, revenue fell short of estimates

Kyntra Bio (KYNB) reported Q3 EPS of $0.04, beating estimates by $3.77, but revenue of $1.76M missed expectations of $1.83M. The stock is down 56.28% over 3 months and 63.22% over 12 months. InvestingPro rates its financial health as 'fair performance'.

KYNB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning KYNB (KYNTRA BIO, INC.). Coverage has been balanced: 0 bullish, 5 neutral, and 0 bearish.

Recent KYNB coverage spans earnings, corporate actions and financial news.

What's driving KYNB

  • Oppenheimer kept Kyntra Bio's rating at Outperform but reduced its price target to $30 from $35, a 14.3% cut. This implies an 837.5% upside from the Nov 16 close of $3.20, according to the firm.

    tradingview.com · Nov 17, 2026

  • EPS beat but revenue missed, setting up a mixed post-earnings tape where investors may focus on whether the revenue shortfall is structural.

    investing.com · Nov 16, 2026

  • Financing dependency for roxadustat Phase 3 is the key risk, while program exits and runway extension reduce near-term liquidity pressure.

    tradingview.com · Nov 16, 2026

  • Termination of FG-3246 reduces pipeline spend, while the roxadustat Phase 3 plan and cash runway into 2028 are key near-term catalysts.

    SEC EDGAR 8-K · Nov 16, 2026

  • The upcoming data releases could drive short-term volatility as investors assess trial progress.

    rttnews.com · Oct 19, 2026

AlphAI scores every news story that mentions KYNB with an AI model for sentiment and relevance, and aggregates insider trades from KYNTRA BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $KYNB

Score
$KYNBMedEarnings

Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments re

$KYNBLowExec change· appointed

KYNTRA BIO, INC. (KYNB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors SAN FRANCISCO, October 1, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member o

Oppenheimer reiterates Kyntra Bio stock rating on debt reduction

Oppenheimer maintained an Outperform rating and $35.00 price target for Kyntra Bio (NASDAQ:KYNB) after the company restructured its royalty financing agreement, reducing obligations to $65M from $125M. The company made a $42.6M payment, eliminating $60M in future obligations while retaining royalty economics. Kyntra Bio has a current ratio of 2.69 and is trading at $7.78, below analyst targets. Oppenheimer expects Phase 3 and Phase 2 data in 2026 and sees improved financial flexibility.

$KYNBMedDebt financing· $65M

KYNTRA BIO, INC. (KYNB): Entry into a Material Definitive Agreement

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation • Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million • Company accelerated payment of $42.6 mi

$KYNBMedAI 8/10

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio (KYNB) reported Q2 2026 earnings with revenue of -$1.5M, net income of $12.0M, and $95.7M in cash. Clinical updates include FG-3246 Phase II enrollment and roxadustat Phase III plans. Management expects cash to last into 2028 and discussed potential partnerships for roxadustat.

Related tickers